Zobrazeno 1 - 10
of 93
pro vyhledávání: '"Stefan Sleijfer"'
Autor:
Stefan Sleijfer, John W.M. Martens, Harmen J.G. van de Werken, Corine M. Beaufort, Anieta M. Sieuwerts, Job van Riet, Nikolas H. Stoecklein, Jaco Kraan, Yorick Sandberg, Peter A. W. te Boekhorst, Martijn P. Lolkema, Wytske M. van Weerden, Anouk C. de Jong, Paul Hamberg, S. Erkens-Schulze, Lisanne F. van Dessel, L. Mout, Thomas L.C. Woo, Ronald de Wit, Rui P L Neves
Publikováno v:
European Journal of Cancer, 150, 179-189. Elsevier Ltd.
Background: Circulating tumour cell (CTC)–derived organoids have the potential to provide a powerful tool for personalised cancer therapy but are restrained by low CTC numbers provided by blood samples. Here, we used diagnostic leukapheresis (DLA)
Autor:
Tanja Fehm, Luc Dirix, Stefan Sleijfer, Paola Gazzaniga, José A. García-Sáenz, Carlos Caldas, Rita Zamarchi, Karthik V. Giridhar, Lorenzo Gerratana, Massimo Cristofanilli, Luis Manso, Dimitrios Mavroudis, Kostandinos Sideras, Meredith M. Regan, Zefei Jiang, Michail Ignatiadis, Rafael Gisbert-Criado, William E. Barlow, François-Clément Bidard, Thomas W. P. Friedl, Klaus Pantel, Evi Lianidou, Daniele Generali, Jean-Yves Pierga, Sabine Riethdorf, Tracy C. Yab, Mark Jesus M. Magbanua, Jose Vidal-Martinez, Jeffrey B. Smerage, Brigitte Rack, Hope S. Rugo, Catherine Alix-Panabières, Lisa A. Carey, Minetta C. Liu, Volkmar Müller, William Jacot, Wolfgang Janni, Elisabetta Munzone, Justin Stebbing, Leon W.M.M. Terstappen, Daniel F. Hayes
Publikováno v:
Cancer Research. 81:GS4-08
Background: Several studies suggest clinical utility of serial circulating tumor cell (CTC) enumeration as a means of assessing response status in metastatic breast cancer (MBC). The aim of this study is to conduct a comprehensive pooled analysis com
Autor:
Jaco Kraan, Leonie L. Zeune, Leon W.M.M. Terstappen, John W.M. Martens, Mai Van, Esther Oomen-de Hoop, Stefan Sleijfer, Pauline A J Mendelaar
Publikováno v:
Molecular Oncology
Molecular Oncology, Vol 15, Iss 1, Pp 116-125 (2021)
Molecular oncology, 15(1), 116-125. Elsevier
Molecular Oncology, 15(1), 116-125. John Wiley & Sons Ltd.
Molecular Oncology, Vol 15, Iss 1, Pp 116-125 (2021)
Molecular oncology, 15(1), 116-125. Elsevier
Molecular Oncology, 15(1), 116-125. John Wiley & Sons Ltd.
Molecular characterization of circulating tumor cells is of high clinical relevance. Since circulating tumor cell (CTC) detection and isolation often rely on cell dimensions, we determined the size of 71 612 CellSearch‐detected CTCs using accept so
Autor:
Milea J. M. Timbergen, Dirk J. Grünhagen, Cornelis Verhoef, Stefan Sleijfer, Anne-Rose W. Schut
Publikováno v:
European Journal of Cancer, 137, 18-29. Elsevier Ltd.
BACKGROUND: This study evaluates the results of the active surveillance (AS) approach in adult patients with desmoid-type fibromatosis (DTF) because AS is advocated as a front-line approach for DTF in the European consensus guidelines.METHODS: A syst
Autor:
Wouter Dercksen, Dinja T. Kruger, Agnes Jager, Inge R. H. M. Konings, John W.M. Martens, Maurice P.H.M. Jansen, Jamal Oulad Hadj, Stefan Sleijfer, Epie Boven
Publikováno v:
Molecular Oncology, Vol 14, Iss 3, Pp 490-503 (2020)
Molecular Oncology, 14, 490-503. John Wiley & Sons Ltd.
Kruger, D T, Jansen, M P H M, Konings, I R H M, Dercksen, W M, Jager, A, Oulad Hadj, J, Sleijfer, S, Martens, J W M & Boven, E 2020, ' High ctDNA molecule numbers relate with poor outcome in advanced ER+, HER2-postmenopausal breast cancer patients treated with everolimus and exemestane ', Molecular oncology, vol. 14, no. 3, pp. 490-503 . https://doi.org/10.1002/1878-0261.12617
Molecular Oncology
Molecular oncology, 14(3), 490-503. Elsevier
Molecular Oncology, 14, 490-503. John Wiley & Sons Ltd.
Kruger, D T, Jansen, M P H M, Konings, I R H M, Dercksen, W M, Jager, A, Oulad Hadj, J, Sleijfer, S, Martens, J W M & Boven, E 2020, ' High ctDNA molecule numbers relate with poor outcome in advanced ER+, HER2-postmenopausal breast cancer patients treated with everolimus and exemestane ', Molecular oncology, vol. 14, no. 3, pp. 490-503 . https://doi.org/10.1002/1878-0261.12617
Molecular Oncology
Molecular oncology, 14(3), 490-503. Elsevier
We determined whether progression-free survival (PFS) in metastatic breast cancer (MBC) patients receiving everolimus plus exemestane (EVE/EXE) varies depending on circulating tumour DNA (ctDNA) characteristics. Baseline plasma cell-free DNA (cfDNA)
Autor:
Tessa Pierson, Zineb Belcaid, Edward van Beelen, Michael Lim, Martine L.M. Lamfers, Denis Routkevitch, Jenneke Kloezeman, Dimitrios Mathios, Mariëlle van der Kaaij, John Choi, Alicia van der Ploeg, Eftychia Stavrakaki, Cor A. Berrevoets, Stefan Sleijfer, Reno Debets, Clemens M F Dirven
Publikováno v:
Neuro-Oncology Advances, 2(1), 1-12. Oxford University Press
Neuro-oncology Advances
Neuro-oncology Advances
BackgroundThe tumor-selective human adenovirus Delta24-RGD is currently under investigation in phase II clinical trials for patients with recurrent glioblastoma (GBM). To improve treatments for patients with GBM, we explored the potential of combinin
Autor:
Hans Gelderblom, Henk-Jan Guchelaar, Jacqueline S. L. Kloth, Neeltje Steeghs, Stefan Sleijfer, Michiel C. Verboom, Ron H.J. Mathijssen, Anna K.L. Reyners, Jesse J. Swen
Publikováno v:
Pharmacogenomics Journal
Pharmacogenomics Journal, 19(5), 473-479. NATURE PUBLISHING GROUP
Pharmacogenomics journal, 19(5), 473-479. Nature Publishing Group
Pharmacogenomics Journal, 19(5), 473-479. Nature Publishing Group
Pharmacogenomics Journal, 19(5), 473-479. NATURE PUBLISHING GROUP
Pharmacogenomics journal, 19(5), 473-479. Nature Publishing Group
Pharmacogenomics Journal, 19(5), 473-479. Nature Publishing Group
Imatinib has a mild toxicity profile, although severe adverse events may develop. In this pharmacogenetic pathway analysis the need for dose reduction and cessation of therapy was tested for an association with single nucleotide polymorphisms (SNPs)
Autor:
Harmen J.G. van de Werken, Linde M. van Veenendaal, Job van Riet, Martijn P. Lolkema, Edwin Cuppen, Heinz-Josef Klümpen, Margot Tesselaar, Bianca Mostert, Ferry A.L.M. Eskens, Stefan Sleijfer, Marcus W. Dercksen, Gerlof D. Valk
Publikováno v:
Nature Communications
Nature Communications, Vol 12, Iss 1, Pp 1-14 (2021)
Nature communications, 12(1):4612. Nature Publishing Group
Nature Communications, 12(1):4612. Nature Publishing Group
Nature Communications, Vol 12, Iss 1, Pp 1-14 (2021)
Nature communications, 12(1):4612. Nature Publishing Group
Nature Communications, 12(1):4612. Nature Publishing Group
Metastatic and locally-advanced neuroendocrine neoplasms (aNEN) form clinically and genetically heterogeneous malignancies, characterized by distinct prognoses based upon primary tumor localization, functionality, grade, proliferation index and diver
Autor:
Teoman Deger, Saskia M. Wilting, Stefan Sleijfer, Elisabeth M. Jongbloed, Agnes Jager, John W.M. Martens
Publikováno v:
Cancers, Vol 13, Iss 1811, p 1811 (2021)
Cancers
Cancers
Simple Summary Currently, the most commonly used method to monitor response to treatment in metastatic breast cancer patients is by radiological imaging. However, these imaging techniques are relatively insensitive and give little to no insight into
Autor:
Bram De Laere, Wendy Onstenk, Ron H.J. Mathijssen, Wytske M. van Weerden, Anieta M. Sieuwerts, Geert-Jan Creemers, John W.M. Martens, Ronald de Wit, Stefan Sleijfer, Paul Hamberg, Aart Beeker, Hielke J. Meulenbeld, Jaco Kraan, Guido Jenster, Luc Dirix, Mai Van, Corine M. Beaufort, Annemieke J.M. Nieuweboer
Publikováno v:
Molecular Oncology, Vol 13, Iss 8, Pp 1795-1807 (2019)
Molecular Oncology
Molecular Oncology, 13(8), 1795-1807. John Wiley & Sons Ltd.
Molecular Oncology
Molecular Oncology, 13(8), 1795-1807. John Wiley & Sons Ltd.
The androgen receptor splice variant (AR-V) 7 in circulating tumor cells (CTCs) is a predictor for resistance to anti-AR-targeted treatment, but not to taxane-based chemotherapy in metastatic castration-resistant prostate cancer (mCRPC). In this stud